Zymeworks Inc.

Zymeworks Inc. is a Delaware-based biotechnology company focused on discovering and developing multifunctional biotherapeutics and managing a portfolio of licensed healthcare assets. Its work centers on antibody-based therapies and related platform technologies for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, often through partnerships with larger pharmaceutical companies.

−83,9 %

−76,6 %

+38,9 %

5.88

5.88

— Zymeworks Inc.
%
Wholly-owned therapeutic pipeline20% Internal drug candidates and platform-derived programs in preclinical and clinical development.
Partnered licensed assets55% Programs out-licensed to pharma partners that can generate milestones, royalties, and option fees.
Platform technology licenses15% Azymetric, EFECT, and related technology access agreements with research and commercial partners.
Development support and drug supply10% Technical support and supply services provided under collaboration agreements.

Zymeworks sells primarily to pharmaceutical and biotechnology partners rather than end patients, because its business...

  • Global pharmaceutical partnersprimary

    Large drug companies that license Zymeworks' platforms or assets and pay milestones, royalties, and option fees.

  • Biotechnology collaboratorsprimary

    Smaller or mid-sized partners that co-develop programs or access platform technologies for specific targets.

  • Regional commercialization partnersprimary

    Partners such as BeOne and Jazz that handle development and commercial activities in defined territories.

  • Research and supply customerssecondary

    Counterparties purchasing drug supply, technical support, or research services under collaboration agreements.

Zymeworks is headquartered in the United States but retains a substantial operating footprint in Canada, where many of...

  • •Headquartered in Delaware, United States
  • •Large employee base in Canada supports R&D operations
  • •Partnered commercialization in Asia, including China, South Korea, Australia, and New Zealand
  • •Global collaboration model creates multi-jurisdiction regulatory exposure
  • •Small operating presence in Singapore, Ireland, and the UK

Zymeworks' strategy is to compound value through royalty growth, milestone income, and selective partnerships while...

01
Grow royalty and milestone revenue from zanidatamab and other partnered assetsshort-term

Recurring partner-driven cash flows can fund R&D and reduce dependence on equity financing.

02
Maintain a partnership-driven development modelmedium-term

Sharing clinical and commercial execution with partners lowers capital needs and execution risk.

03
Advance selected wholly-owned pipeline programsmedium-term

Internal programs preserve long-term upside and keep the platform relevant beyond current partnered assets.

04
Expand platform value through new collaborations and external assetslong-term

Additional partnerships can monetize technology and diversify future milestone streams.

Zymeworks depends heavily on third-party partners for manufacturing, clinical execution, and commercialization, so...

high

Dependence on third-party manufacturing

The company does not own manufacturing facilities and relies on contract manufacturers for clinical and commercial supply.

Scope
Product candidates and approved products
Materiality
high
high

Dependence on partners for clinical and commercial execution

Partners control key development, regulatory, and commercialization activities in several programs and territories.

Scope
Zanidatamab and partnered pipeline
Materiality
high
high

Intellectual property protection

The business model relies on patents, trade secrets, and platform know-how to support licensing and royalty economics.

Scope
Azymetric, EFECT, and product candidates
Materiality
high
high

Regulatory approval and clinical development risk

Pipeline value depends on successful trials, filings, and approvals across multiple jurisdictions.

Scope
Oncology, inflammation, autoimmune programs
Materiality
high
medium

Revenue concentration and timing variability

Revenue is driven by milestone events, option fees, and royalties that can be uneven quarter to quarter.

Scope
Partner agreements
Materiality
medium
ASC 606 collaboration revenue recognition
Can shift revenue between periods and create quarter-to-quarter volatility
Variable consideration for milestones
Affects reported revenue and deferred revenue balances
Foreign exchange
Can affect other income (expense) and comparability
Stock-based compensation
Raises operating expense and affects non-cash cost analysis

Zivo Bioscience, Inc.

ZIVO · Biological Products, (No Diagnostic Substances)

CYPHERPUNK TECHNOLOGIES INC.

CYPH · Pharmaceutical Preparations

ZyVersa Therapeutics, Inc.

ZVSA · Pharmaceutical Preparations

ZYNEX INC

ZYXIQ · Electromedical & Electrotherapeutic Apparatus

Zomedica Corp.

ZOMDF · Pharmaceutical Preparations

Zeo ScientifiX, Inc.

ZEOX · Biological Products, (No Diagnostic Substances)

: 29.4.2026